Newly customized cationic ẞ-cyclodextrins as potential nanovectors for gene delivery

Area of Science:

• Biomaterials Science
• Nanotechnology
• Gene Therapy

Background:

• Clinical gene therapy is hindered by the lack of safe and efficient delivery vectors.
• Beta-cyclodextrins (β-CDs) offer biocompatibility and tunable structures, making them promising for vector development.

Purpose of the Study:

• To synthesize and characterize novel cationic β-CD derivatives as nanovectors (NVs) for gene delivery.
• To evaluate the biopharmaceutical performance of these NVs in vitro, including transfection and gene silencing efficiencies.

Main Methods:

• Synthesis of three cationic β-CD derivatives (CD1, CD2, CD3) and their formulation into NVs with plasmid DNA (pGFP) or siRNA.
• Physico-chemical characterization using TEM, Cryo-EM, SAXS, size, PdI, and zeta potential analysis.
• In vitro assessment of cytotoxicity (MTT assay), transfection efficiency (flow cytometry, fluorescence microscopy), and gene silencing in HeLa cells.

Main Results:

• All β-CD-based NVs exhibited suitable sizes (<200 nm) and low polydispersity index (PdI <0.3).
• CD1 formulation showed superior performance, achieving gene expression and silencing efficiencies comparable to commercial Lipofectamine.
• Structural analysis revealed a hierarchical arrangement within the NV complexes, confirming efficient nucleic acid binding.

Conclusions:

• Cationic β-CD derivatives, particularly CD1, show significant promise as effective and biocompatible nanovectors for gene delivery applications.
• The developed NVs offer a potential solution to current limitations in clinical gene therapy vector safety and efficiency.